3 results match your criteria: "SS Antonio & Biagio and C. Arrigo Hospital[Affiliation]"
Pulmonary function and bronchopulmonary dysplasia classification: insights from the Spanish Registry.
Eur J Pediatr
September 2024
Pediatric Pulmonologist at Pulmonology Department, Virgen Arrixaca University Hospital Murcia, Murcia, Spain.
In 2016, the Spanish Research Group on Bronchopulmonary Dysplasia (BPD) (GEIDIS) established a national registry with participation of 66 hospitals to collect information on clinical characteristics and long-term outcomes of BPD infants into adulthood. The aim of this observational study is to examine forced spirometry data in early childhood and to assess their correlation with the respiratory support required at 36 weeks postmenstrual age (PMA). The study analyzed data from preterm infants with BPD born between January 2016 and December 2017 who underwent forced spirometry at 5-7 years of age.
View Article and Find Full Text PDFEtrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Lancet Gastroenterol Hepatol
January 2022
Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute, Biomedical Research Networking Center in Hepatic and Digestive Diseases, Barcelona, Spain. Electronic address:
Article Synopsis
- Etrolizumab is an anti-β7 integrin monoclonal antibody that showed promise in improving remission rates for patients with moderately to severely active ulcerative colitis in previous studies, leading to the HIBISCUS trials to further assess its effectiveness compared to adalimumab and placebo.
- The HIBISCUS studies were multicenter, double-blind, randomized trials involving adult patients with specific inclusion criteria, randomly assigning participants to receive etrolizumab, adalimumab, or placebo while ensuring that both the patients and study staff remained unaware of the treatment assignments.
- The main goal of these studies was to measure remission rates at week 10, using a specific formula to define remission, while also performing
Risk factors and bronchopulmonary dysplasia severity: data from the Spanish Bronchopulmonary Dysplasia Research Network.
Eur J Pediatr
February 2022
Neonatologist at Neonatology Department, Gregorio Marañón University Hospital, O'Donnell 48 street, 28009, Madrid, Spain.
GEIDIS is a national-based research-net registry of patients with bronchopulmonary dysplasia (BPD) from public and private Spanish hospitals. It was created to provide data on the clinical characterization and follow-up of infants with BPD until adulthood. The purpose of this observational study was to analyze the characteristics and the impact of perinatal risk factors on BPD severity.
View Article and Find Full Text PDF